Expanded Access for CC-486

Celgene1 个研究点分布在 1 个国家开始时间: 2018年10月29日最近更新: 2020年9月18日

适应症

试验速览

This is an expanded access program (EAP) for eligible participants designed to provide access to CC-486.

•Adult patients with documented acute myelogenous leukemia (AML) in their first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment, who seek treatment with CC-486 as monotherapy to maintain their CR or CRi.

•Patients with AML in CR/CRi who plan to proceed to or are waiting for a bone marrow transplant
•Patients who have received a bone marrow transplant for the treatment of AML
•Treatment of AML patients with relapse or refractory disease
•Pregnant or breast-feeding females
•Patient meets enrollment criteria and can participate in a disease-specific clinical trial

发起方

申办方类型

Industry

责任方

Sponsor

Loading locations...